About Cytokinetics, Incorporated - Common Stock (CYTK)
Cytokinetics is a biotechnology company that focuses on the development of novel muscle therapeutics. The company is dedicated to discovering and advancing treatments for a range of diseases characterized by muscle weakness and impaired muscle function, notably in conditions such as heart failure and neuromuscular diseases. Cytokinetics utilizes its expertise in muscle biology to create innovative therapies that may enhance muscle performance, improve patient outcomes, and ultimately transform the standard of care in these areas. Through rigorous research and clinical trials, Cytokinetics aims to provide groundbreaking options for patients with unmet medical needs tied to muscle-related disorders. Read More
SAN DIEGO, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of persons and entities that purchased or otherwise acquired Cytokinetics, Inc. (NASDAQ: CYTK) securities between December 27, 2023 and May 6, 2025. Cytokinetics is a biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised.
Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, announces that a securities fraud class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Cytokinetics, Incorporated (“Cytokinetics” or the “Company”) (NASDAQ: CYTK) common stock between December 27, 2023 and May 6, 2025, inclusive (the “Class Period”). Cytokinetics investors have until November 17, 2025 to file a lead plaintiff motion.
NEW YORK - September 19, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in Cytokinetics, Incorporated (NASDAQ: CYTK) of a class action securities lawsuit.
The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Cytokinetics, Incorporated (“Cytokinetics” or “the Company”) (NASDAQ: CYTK) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Cytokinetics (CYTK) To Contact Him Directly To Discuss Their Options
Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Cytokinetics, Incorporated (“Cytokinetics” or the “Company”) (NASDAQ: CYTK) common stock between December 27, 2023 and May 6, 2025, inclusive (the “Class Period”). Cytokinetics investors have until November 17, 2025 to file a lead plaintiff motion.
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Cytokinetics To Contact Him Directly To Discuss Their Options
Shares of Cytokinetics are trading sharply higher Tuesday. The company presented new long-term safety and efficacy data for its investigational drug, aficamten.
The session on Tuesday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session.
As we await the opening of the US market on Tuesday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.
Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Cytokinetics, Incorporated (“Cytokinetics” or the “Company”) (NASDAQ: CYTK) investors concerning the Company’s possible violations of the federal securities laws.
